Company Overview and News
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
In general, I'm not a big fan of commodity investing. Commodities are highly speculative, meaning massive potential upside but also the prospect of huge losses. In many cases, too much hinges on uncertain government policies. On top of that, a lot of the popular commodity investment vehicles, such as ETFs and ETNs, are structurally flawed. This means they massively underperform the underlying commodities over time.
Spot gold had dipped 0.2 per cent to $1,309.99 per ounce by 0949 GMT. - Bloomberg
Spot gold rose 0.3 per cent to $1,321.20 per ounce at 0045 GMT, after marking the highest since April 26 at $1,325.96 in the previous session. - istock.com/kuldeepoo8
Spot gold had fallen 0.1 per cent to $1,311.26 per ounce by 0053 GMT. US gold futures for June delivery slipped 0.1 per cent to $1,311.40 per ounce.
Gold prices edged up in early trade on Monday as the dollar took a breather after climbing to its highest level this year in the previous session.
Spot gold was nearly unchanged at $1,311.61 per ounce at 0113 GMT, and on track for a third consecutive weekly decline.
Spot gold was up 0.2 per cent at $1,306.51 per ounce at 0118 GMT. - REUTERS
Comex gold futures are hovering near five-week lows hit in the previous session, pressured by a stronger dollar and a rise in US Treasury yields. Markets are now waiting for the European Central Bank’s monetary policy decision later in the day.
Although gold has been acting pretty strong over the last three months, it was not able to breakout through the massive resistance zone between 1,350 USD and 1,375 USD so far! Actually, all that did happen since the top in January was a tricky and confusing sideways consolidation. Investors and traders want to avoid such a challenging and trendless period in any market, as it usually creates too many misleading signals.
Longer-term drivers of capital to risky assets remain in place and are a drag against gold.
Spot gold rose 0.4 per cent to $1,339.71 an ounce as of 0324 GMT, and was set for a weekly gain of 0.5 per cent
Rhetoric between the U.S. and Russia ahead of a possible confrontation in Syria has precious metals and relative securities getting a bid.
Macro backdrop for gold likely to be sweeter for longer. But U.S.-China trade dispute constitutes a key risk.
Ray Dalio, the billionaire founder of hedge fund Bridgewater Associates, said that he's increasingly nervous about President Trump's antagonistic stance towards China.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...